Effects of Omega-3 Fatty Acid Supplementation on Lipid Levels in Endstage Renal Disease Patients

Bowden, Rodney G.; Jitomir, J; Wilson, Ronald L.; Gentile, Mindy

doi:10.1053/j.jrn.2009.01.030

Cited by 23 publications

(48 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the initial electronic search, 285 manuscripts were identified, of which 243 were excluded including duplicates, study with other design, and unrelated studies. The full text of 42 manuscripts was retrieved, and after detailed evaluation, 23 RCTs including 20 datasets were finally selected for meta-analysis1112131415161718192021222324252627282930313233. No new eligible studies were identified in manual search.…”

Section: Resultsmentioning

confidence: 99%

“…The follow-up duration of RCTs ranged from 2 to 6 months, and the number of patients enrolled in individual RCT ranged from 15 to 206. Ten trials were conducted in Asia12141516242526273133, seven in America11181920283032, two in Europe172329, and one in Africa13. The quality of RCTs was assessed using the Jadad score34 (Table 1), and the scores more than 3 were regarded as high quality trials.…”

Section: Resultsmentioning

confidence: 99%

“…The quality of RCTs was assessed using the Jadad score34 (Table 1), and the scores more than 3 were regarded as high quality trials. Two trials had a score of 51718, six trials scored 412161931, six trials scored 3112023242628, four trials scored 214152125, and the remaining two trials scored 11327.…”

Section: Resultsmentioning

confidence: 99%

“…Khosroshahi et al 16. and Bowden et al 18. suggested that O3FA significantly reduced the LDL, whereas other trials reported no significant difference1314.…”

Section: Discussionmentioning

confidence: 97%

“…Several RCTs1112131415 have demonstrated that supplementation of O3FA may lower CVD risk factors, whereas other RCTs have revealed inconsistent results1617181920212223242526272829. Hence, in this meta-analysis, RCTs were used to determine the role of O3FA supplementation on associated serum lipids and vascular inflammation markers in patients with ESRD, and assess the role of O3FA supplementation in specific subpopulations.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Effect of omega-3 fatty acid supplementation on serum lipids and vascular inflammation in patients with end-stage renal disease: a meta-analysis

Sun

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Omega-3 fatty acids (O3FAs) are associated with lower cardiovascular disease (CVD) risk in adults. However, this association in patients with end-stage renal disease (ESRD) remains controversial prompting the need for investigation into the role of O3FAs on serum lipids and vascular inflammation markers. The present meta-analysis summarized the effects of O3FA supplementation on serum lipids and vascular inflammatory markers in patients with ESRD. PubMed, EmBase, and the Cochrane Library were searched to identify randomized controlled trials (RCTs) focused on serum lipids and vascular inflammation markers in patients with ESRD. Standard mean differences (SMD) were used to measure the effect of O3FA supplementation on serum lipids and vascular inflammatory markers. The final pooled analysis included 20 RCTs involving 1,461 patients with ESRD. The results indicated that O3FA supplementation reduced TG by 0.61, LDL by 0.35 and CRP by 0.56. However, O3FA had no significant effect on TC, HDL, albumin, hemoglobin, homocysteine, DBP, glucose, lipoprotein(a), and ferritin. O3FA supplementation is associated with lower several serum lipids and vascular inflammation markers in patients with ESRD.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Khosroshahi et al 16. and Bowden et al 18. suggested that O3FA significantly reduced the LDL, whereas other trials reported no significant difference1314.…”

Section: Discussionmentioning

confidence: 97%